Morria Biopharmaceuticals Announces Results From Clinical Study Of MRX-4 In Allergic Rhinitis Patients
Morria Biopharmaceuticals announced the preliminary safety results from its Phase I safety and tolerability study of MRX-4 in 16 patients suffering from allergic rhinitis (AR).
MRX-4 was nasally administered as a single dose once a week for four consecutive weeks. The first administration was given without a nasal allergen challenge (NAC) while the subsequent three were carried out in conjunction with a NAC. The protocol was double-blinded and placebo-controlled. During the trial, no adverse effects were observed with blood analysis and pharmacokinetic data further indicating safety.
"We are entirely satisfied with these results," said Dr. Yuval Cohen, President of Morria. "They mark an important milestone in our clinical development plan, which aims at offering a potentially safer and more effective treatment option in the multi-billion dollar AR market." Morria plans to initiate a Phase II efficacy clinical study with 175 patients, who will be treated for six days prior to allergen challenge.
ABOUT ALLERGIC RHINITIS
Allergic rhinitis is a common condition that affects nearly 59 million people in the United States (nearly 20 percent of the population) with a market of close to $4 billion. Allergic rhinitis is characterized by inflammation of the nasal membranes accompanied by symptoms that may include sneezing, nasal congestion, nasal itching and rhinorrhea.